DFFN Diffusion Pharmaceuticals Dashboard

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Company profile

Ticker

DFFN

Exchange

NASDAQ

Website

diffusionpharma.com/

CEO

Robert J. Cobuzzi

Incorporated

Delaware

Location

Virginia

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC

SEC CIK

0001053691

Corporate docs

Articles of Incorporation & Bylaws

IRS number

300645032

DFFN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

12 Health Care Stocks Moving In Thursday's After-Market Session

18 Feb 21

Gainers ClearPoint Neuro (NASDAQ:CLPT) stock rose 8.48% to $27.99 during Thursday's after-market session. This security traded at a volume of 10.5K shares come close, making up 4.13% of its average volume over the last 100 days. The market value of their outstanding shares is at $477.9 million.

The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout

18 Feb 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)

Stocks That Hit 52-Week Highs On Wednesday

17 Feb 21

This morning 194 companies reached new 52-week highs.

The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal

17 Feb 21

12 Health Care Stocks Moving In Tuesday's Intraday Session

16 Feb 21

Press releases

Pro users get this 30m faster

Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

4 Mar 21

CHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the

Diffusion Pharmaceuticals Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

18 Feb 21

CHARLOTTESVILLE, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies to deliver oxygen

Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock

17 Feb 21

CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies to deliver oxygen

Thinking about buying stock in Diffusion Pharmaceuticals, Northern Dynasty Minerals, Zomedica, Sundial Growers, or Citius Pharmaceuticals?

17 Feb 21

Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?

16 Feb 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 Nov 20

6 Mar 21

31 Dec 21

Financial summary

Financial statements Chart DFFN financial data

Quarter (USD)	Sep 20	Jun 20	Mar 20	Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 19	Dec 18	Dec 17	Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	21.91M	21.91M	21.91M	21.91M	21.91M	21.91M
Cash burn (monthly)	1.22M	(positive/no burn)	1.76M	1.24M	1.17M	1.03M
Cash used (since last report)	6.32M	n/a	9.13M	6.47M	6.08M	5.33M
Cash remaining	15.59M	n/a	12.78M	15.44M	15.83M	16.58M
Runway (months of cash)	12.8	n/a	7.3	12.4	13.5	16.2

Beta Read what these cash burn values mean

Recent insider trades

DFFN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Mar 21	William Karl Hornung	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	80,069	88.88K	80,069
1 Mar 21	William Karl Hornung	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	122,771	136.28K	122,771
1 Mar 21	William Robert Elder	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	62,522	69.4K	62,522
1 Mar 21	William Robert Elder	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	87,684	97.33K	87,684
1 Mar 21	Christopher D Galloway	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	81,537	90.51K	81,537
1 Mar 21	Christopher D Galloway	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	27,180	30.17K	27,180
1 Mar 21	Cobuzzi Robert Joseph Jr.	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	161,139	178.86K	161,139
1 Mar 21	Cobuzzi Robert Joseph Jr.	Stock Option Common Stock	Grant	Aquire A	No	No	1.11	53,713	59.62K	53,713
17 Nov 20	William Robert Elder	Common Stock	Buy	Aquire P	No	No	0.63	5,000	3.15K	15,000
16 Nov 20	William Robert Elder	Common Stock	Buy	Aquire P	No	No	0.67	10,000	6.7K	10,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

DFFN institutional ownership history Ownership history

4.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	21	25	-16.0%
Opened positions	5	8	-37.5%
Closed positions	9	7	+28.6%
Increased positions	3	6	-50.0%
Reduced positions	4	7	-42.9%

13F shares	Current	Prev Q	Change
Total value	3.86M	4.31M	-10.5%
Total shares	4.85M	5.12M	-5.2%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Renaissance Technologies	2.83M	$2.25M	-5.2%
BLK Blackrock	830.47K	$660K	0.0%
Vanguard	393.23K	$312K	+11.6%
Geode Capital Management	255.69K	$203K	0.0%
NTRS Northern Trust	107.89K	$86K	-1.3%
Two Sigma Investments	106.34K	$85K	NEW
Fan Yu	89.85K	$71K	NEW
Two Sigma Advisers	69.7K	$55K	NEW
Raymond James Financial Services Advisors	40K	$32K	0.0%
Advisor	29.48K	$24K	-8.2%

Largest transactions	Shares	Bought/sold	Change
VIRT Virtu Financial	0	-155.83K	EXIT
Renaissance Technologies	2.83M	-155.81K	-5.2%
Two Sigma Investments	106.34K	+106.34K	NEW
GS Goldman Sachs	0	-98.12K	EXIT
Fan Yu	89.85K	+89.85K	NEW
Two Sigma Advisers	69.7K	+69.7K	NEW
Citadel Advisors	0	-52.66K	EXIT
Vanguard	393.23K	+40.95K	+11.6%
HCR Wealth Advisors	0	-30K	EXIT
Squarepoint Ops	0	-24.16K	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Curis

Management Discussion

We recognized $3.1 million in R&D expenses during the three months ended September 30, 2020 compared to $1.7 million during the three months ended September 30, 2019. A significant portion of this increase was attributable to R&D expenses related to the 100-303 COVID Trial initiated in September 2020 and our related ramp-up, including a $0.4 million increase in manufacturing costs and a $1.0 million increase in clinical trial and other R&D expenses. The overall increase in R&D expense also includes a $0.1 million increase in costs associated with the PHAST Trial, primarily costs related to winding down the trial. These increases in R&D expenses were offset in part by a $0.1 million decrease in R&D related salaries, wages and stock-based compensation expense.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accomplish, adjudication, adjunctive, adjunctively, administered, afflicted, Affordable, air, allosteric, ambulance, analyzed, appointed, arrangement, artery, ascending, attempt, avoiding, belief, Bioconnect, biopharmaceutical, Biotech, blocked, bonding, breakdown, breathing, broad, Bucharest, cell, Christopher, claudication, Cobuzzi, complex, complicated, complicating, complication, concept, Conference, confirmed, contributor, Corona, counsel, coupled, COVID, CRO, cumulative, daily, dense, detail, die, director, Education, efficient, Elder, employee, encountered, endpoint, energy, enhance, equipment, evenly, eventually, excessive, expansion, expediting, experimental, explained, explicitly, extension, extracorporeal, factor, final, frequency, fully, Galloway, greater, HC, heading, high, Hollingsworth, hydrogen, hyperoxia, identification, implied, infiltration, innovative, intermittent, intractable, invalidation, ischemia, Jane, knowledge, leadership, Litigation, lt, matrix, membrane, metabolic, modification, NOL, onset, opportunistic, ordinary, Orphan, outsource, oversee, ownership, oximetry, peripheral, persistence, pharmacodynamic, pharmacokinetic, political, postponed, predecessor, preferentially, presidential, Prevention, prioritizing, proceed, produce, progressing, promulgated, proof, prospectively, publicly, pulse, put, quantify, Reconciliation, red, Reform, regimen, relevant, remeasured, repeal, replacement, resignation, responded, retirement, Robert, Romania, room, Secondary, separation, sequential, Showcase, stockholder, streamline, subgroup, subsidized, successfully, summer, supplemental, taxable, team, tolerability, tolerable, topline, toxicity, Trail, unamended, Union, unknown, variety, ventilation, vessel, virtual, warrent, water, William, wind, winding

Removed: administrative, assumed, bring, bulk, cardiovascular, cellular, Codification, commencement, commercial, competing, continuing, cooperation, criteria, crocetinate, cut, dependent, deprivation, DSMB, emergency, entering, exploring, forward, growth, hire, improving, inaccurate, inherent, label, met, move, multiforme, NDA, neurodegenerative, omitted, open, permission, practice, PreHospital, promote, protect, randomization, ranging, reader, safely, scope, selectively, sodium, spend, strong, survival, test, tested, transcrocetinate, treated, tumor, type, UCLA, University, unmet, untreated, utility

From filing 10-Q 2020 Q3